<?xml version="1.0" encoding="UTF-8"?>
<abstract id="15722369">
  <title>
    <s id="0" section="title">
      <group id="0">Quetiapine</group>
      and
      <group id="1">rivastigmine</group>
      and cognitive decline in Alzheimer 's disease : randomised double blind placebo controlled trial .
    </s>
  </title>
  <annotated>
    <s id="4" section="participants">
      <ps>93</ps>
      patients with Alzheimer 's disease , dementia , and clinically significant agitation .
    </s>
    <s id="6" section="main_outcome_measures">
      <outcome id="1">
        Agitation  (  Cohen-Mansfield
        <short>agitation  inventory</short>
        )
      </outcome>
      and
      <outcome id="0" type="good">
        cognition  (
        <short>severe  impairment  battery</short>
        )
      </outcome>
      at
      <time id="0">baseline</time>
      and at
      <time id="1">6  weeks</time>
      and
      <time id="2">26  weeks</time>
      .
    </s>
    <s id="7" section="main_outcome_measures">
      The primary outcome was
      <outcome id="1">agitation  inventory</outcome>
      at
      <time id="1">6  weeks</time>
      .
    </s>
    <s id="8" section="results">
      31 patients were randomised to each group , and 80 ( 86 % ) started treatment (
      <gs group="1">25</gs>
      <group id="1">rivastigmine</group>
      ,
      <gs group="0">26</gs>
      <group id="0">quetiapine</group>
      ,
      <gs group="2">29</gs>
      <group id="2">placebo</group>
      ) , of whom 71 ( 89 % ) tolerated the maximum protocol dose ( 22
      <group id="1">rivastigmine</group>
      , 23
      <group id="0">quetiapine</group>
      , 26
      <group id="2">placebo</group>
      ) .
    </s>
    <s id="9" section="results">
      Compared with
      <group id="2">placebo</group>
      , neither group showed significant differences in improvement on the
      <outcome id="1">agitation  inventory</outcome>
      either at
      <time id="1">6  weeks</time>
      or
      <time id="2">26  weeks</time>
      .
    </s>
    <s id="10" section="results">
      56 patients scored &gt; 10 on the
      <outcome id="0" type="good">severe  impairment  battery</outcome>
      at
      <time id="0">baseline</time>
      , 46 ( 82 % ) of whom were included in the analysis at
      <time id="1">6  week  follow  up</time>
      (
      <on group="1" outcome="0">14</on>
      <group id="1">rivastigmine</group>
      ,
      <on group="0" outcome="0">14</on>
      <group id="0">quetiapine</group>
      ,
      <on group="2" outcome="0">18</on>
      <group id="2">placebo</group>
      ) .
    </s>
    <s id="11" section="results">
      For
      <group id="0">quetiapine</group>
      the change in
      <outcome id="0" type="good">severe  impairment  battery  score</outcome>
      from
      <time id="0">baseline</time>
      was estimated as an average of - 14.6 points ( 95 % confidence interval - 25.3 to - 4.0 ) lower ( that is , worse ) than in the
      <group id="2">placebo  group</group>
      at
      <time id="1">6  weeks</time>
      ( P = 0.009 ) and - 15.4 points ( -27.0 to - 3.8 ) lower at
      <time id="2">26  weeks</time>
      ( P = 0.01 ) .
    </s>
    <s id="12" section="results">
      The corresponding changes with
      <group id="1">rivastigmine</group>
      were - 3.5 points ( -13.1 to 6.2 ) lower at
      <time id="1">6  weeks</time>
      ( P = 0.5 ) and - 7.5 points ( -21.0 to 6.0 ) lower at
      <time id="2">26  weeks</time>
      ( P = 0.3 ) .
    </s>
  </annotated>
  <fulltext>Quetiapine and rivastigmine and cognitive decline in Alzheimer 's disease : randomised double blind placebo controlled trial . To determine the respective efficacy of quetiapine and rivastigmine for agitation in people with dementia in institutional care and to evaluate these treatments with respect to change in cognitive performance . Randomised double blind ( clinician , patient , outcomes assessor ) placebo controlled trial . Care facilities in the north east of England . 93 patients with Alzheimer 's disease , dementia , and clinically significant agitation . Atypical antipsychotic ( quetiapine ) , cholinesterase inhibitor ( rivastigmine ) , or placebo ( double dummy ) . Agitation ( Cohen-Mansfield agitation inventory ) and cognition ( severe impairment battery ) at baseline and at 6 weeks and 26 weeks . The primary outcome was agitation inventory at 6 weeks . 31 patients were randomised to each group , and 80 ( 86 % ) started treatment ( 25 rivastigmine , 26 quetiapine , 29 placebo ) , of whom 71 ( 89 % ) tolerated the maximum protocol dose ( 22 rivastigmine , 23 quetiapine , 26 placebo ) . Compared with placebo , neither group showed significant differences in improvement on the agitation inventory either at 6 weeks or 26 weeks . 50 6 patients scored &gt; 10 on the severe impairment battery at baseline , 46 ( 82 % ) of whom were included in the analysis at 6 week follow up ( 14 rivastigmine , 14 quetiapine , 18 placebo ) . For quetiapine the change in severe impairment battery score from baseline was estimated as an average of - 14.6 points ( 95 % confidence interval - 25.3 to - 4.0 ) lower ( that is , worse ) than in the placebo group at 6 weeks ( P = 0.009 ) and - 15.4 points ( -27.0 to - 3.8 ) lower at 26 weeks ( P = 0.01 ) . The corresponding changes with rivastigmine were - 3.5 points ( -13.1 to 6.2 ) lower at 6 weeks ( P = 0.5 ) and - 7.5 points ( -21.0 to 6.0 ) lower at 26 weeks ( P = 0.3 ) . Neither quetiapine nor rivastigmine are effective in the treatment of agitation in people with dementia in institutional care . Compared with placebo , quetiapine is associated with significantly greater cognitive decline .</fulltext>
  <ignored>
    <s id="1" section="objectives">
      To determine the respective efficacy of
      <group id="0">quetiapine</group>
      and
      <group id="1">rivastigmine</group>
      for agitation in people with dementia in institutional care and to evaluate these treatments with respect to change in
      <outcome id="0" type="good">cognitive  performance</outcome>
      .
    </s>
    <s id="2" section="design">Randomised double blind ( clinician , patient , outcomes assessor ) placebo controlled trial .</s>
    <s id="3" section="setting">Care facilities in the north east of England .</s>
    <s id="5" section="intervention">
      <group id="0">
        Atypical  antipsychotic  (
        <short>quetiapine</short>
        )
      </group>
      ,
      <group id="1">
        cholinesterase  inhibitor  (
        <short>rivastigmine</short>
        )
      </group>
      , or
      <group id="2">
        <short>placebo</short>
        (  double  dummy  )
      </group>
      .
    </s>
    <s id="13" section="conclusions">
      Neither
      <group id="0">quetiapine</group>
      nor
      <group id="1">rivastigmine</group>
      are effective in the treatment of
      <outcome id="1">agitation</outcome>
      in people with dementia in institutional care .
    </s>
    <s id="14" section="conclusions">
      Compared with
      <group id="2">placebo</group>
      ,
      <group id="0">quetiapine</group>
      is associated with significantly greater
      <outcome id="0" type="good">cognitive  decline</outcome>
      .
    </s>
  </ignored>
</abstract>

